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Abstract
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) converts inert glucocorticoids into active forms, thereby
increasing intracellular glucocorticoid levels, important to restrain acute inflammation. 11β-HSD1 is induced by pro-
inflammatory cytokines in a variety of cells. Here, we show 11β-HSD1 expression in human A549 epithelial cells is
increased by pro-inflammatory cytokines (IL-1α/TNFα) via the P2 promoter of the HSD11B1 gene. Inhibition of p38
MAPK attenuated the pro-inflammatory cytokine induction of mRNA encoding 11β-HSD1 as well as that encoding C/
EBPβ. IL-1α/TNFα-induced phosphorylation of C/EBPβ at Thr235 was also attenuated by p38 MAPK inhibition
suggesting involvement of a p38 MAPK-C/EBPβ pathway. siRNA-mediated knock-down of C/EBPβ and NF-κB/RelA
implicated both transcription factors in the IL-1α/TNFα induction of HSD11B1 mRNA. Transient transfections of
HSD11B1 promoter-reporter constructs identified the proximal region of the P2 promoter of HSD11B1 as essential for
this induction. IL-1α increased binding of C/EBPβ to the HSD11B1 P2 promoter, but this was not observed for NF-κB/
RelA, suggesting indirect regulation by NF-κB/RelA. Ectopic expression of mutant chicken C/EBPβ constructs unable
to undergo phosphorylation at the threonine equivalent to Thr235 attenuated the IL-1α-induction of HSD11B1,
whereas mimicking constitutive phosphorylation of Thr235 (by mutation to aspartate) increased basal expression of
HSD11B1 mRNA without affecting IL-1α-induced levels. These data clearly demonstrate a role for both C/EBPβ and
NF-κB/RelA in the pro-inflammatory cytokine induction of HSD11B1 in human epithelial cells and show that p38
MAPK-induced phosphorylation of C/EBPβ at Thr235 is critical in this.
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Introduction
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1)
catalyses the conversion of the intrinsically inert
glucocorticoids, cortisone and 11-dehydrocorticosterone, to
active forms; cortisol and corticosterone, respectively, thus
increasing intracellular glucocorticoid action [1]. Deficiency in,
or inhibition of, 11β-HSD1 exacerbates acute inflammation
although it is protective against the low-grade chronic
inflammation associated with metabolic and cardiovascular
disease [2,3]. 11β-HSD1 expression is increased at sites of
inflammation, including in arthritis [4,5], obesity [6,7] and
atherosclerosis [8], possibly mediated by the pro-inflammatory
cytokines, IL-1α/β and TNFα, which increase levels of mRNA
encoding 11β-HSD1 in a variety of cells [2]. The HSD11B1
gene encoding 11β-HSD1 is transcribed from two different
promoters, P1 and P2, which by RNA splicing produce the
same protein [9]. Whilst activity of the P2 promoter is
dependent on members of the CCAAT/enhancer binding
protein (C/EBP) transcription factor family [9,10], the P1
promoter is C/EBP-independent [9]. Here we used A549
human lung epithelial cells, because unlike most cell lines,
A549 cells express endogenous 11β-HSD1 and have
previously been used as a cell model to demonstrate a
requirement for C/EBPβ in glucocorticoid-regulation of the 11β-
HSD1 promoter [11].
Previous work has associated IL-1 and TNFα induction of
HSD11B1 in human hepatoma cells with the p38 MAPK
pathway and C/EBPβ [12] and in mouse mesenchymal stromal
cells, with NF-κB signalling [13]. The latter is mediated via the
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P1 promoter. Raised levels of IL-1α/β and TNFα are a common
feature of inflammation. These cytokines bind to cell surface
receptors to activate, among others, the nuclear factor kappa B
(NF-κB) and mitogen-activated protein kinase (MAPK)
signalling pathways [14–17]. Key downstream mediators/
effectors of inflammatory signalling include NF-κB [18] and the
C/EBP members, C/EBPβ and C/EBPδ [19–21]. Two main
isoforms of C/EBPβ are produced from CEBPB mRNA; the
liver-enriched activator protein (LAP), and the liver-enriched
inhibitor protein (LIP) which acts as inhibitor of transcription
(although in some cases it may also act as co-activator [22]).
The NF-κB family of transcription factors encompasses five
proteins: RelA (p65), RelB, c-Rel, p50 and p52, with RelA
being typically the active component of NF-κB activation
complexes [18].
Here, we have investigated the involvement of p38 MAPK, C/
EBPβ and NF-κB pathway in the pro-inflammatory induction of
HSD11B1 in the cytokine responsive human lung A549
epithelial cell line [11].
Materials and Methods
Cell culture
Human lung epithelial A549 cells were maintained in
Dulbecco’s Modified Eagle’s Medium (DMEM; Lonza,
Tewkesbury, UK), supplemented with 10% fetal bovine serum
(Lonza), 100U/ml penicillin and 100µg/ml streptomycin as
previously described [11]. CCRF-CEM human leukemia cells
were cultured in RPMI 1640 (Lonza) supplemented with 10%
fetal bovine serum (Lonza), 100U/ml penicillin and 100µg/ml
streptomycin as described [23].
Unless stated otherwise, A549 cells were treated with
10ng/ml IL-1α (R&D Systems, MA, USA) or 20ng/ml TNFα
(R&D Systems) for 24h at 37°C in serum-free DMEM medium
supplemented with 100U/ml penicillin and 100µg/ml
streptomycin. In the experiments designed to inhibit MAPK
pathways, inhibitors of p38 (10µM SB203580; Invitrogen,
Paisley, UK), c-Jun N-terminal kinase II (JNK II; 20µM
SP600125; Calbiochem, Darmstadt, Germany) or mitogen-
activated protein kinase/extracellular signal-regulated kinase
1/2 (MEK1/2; 0.5µM PD0325901; Calbiochem) were added 1h
prior to treatment with IL-1α. Inhibitors were all dissolved in
DMSO and diluted in serum-free DMEM for addition to cells
(final concentration of DMSO was ≤0.1%). For RNA analysis,
cells were collected 24h following addition of IL-1α. For protein
analysis, cells were collected at various times ranging from
15min to 6h. Cycloheximide (CHX, 0.1µM), which was used to
inhibit de novo protein synthesis, was added to cells 1h prior to
IL-1α/TNFα treatment for 4h.
RNA extraction and analysis
A549 cells were harvested in Trizol (Invitrogen) and RNA
extracted as described [11]. RNA (1µg) was reversed
transcribed using SuperScript III (Invitrogen) as described [24]
and amplified by non-quantitative PCR or by real-time
quantitative (q)PCR using a Roche LightCycler 480. In the
assays designed to test the usage of the HSD11B1 P1 and P2
promoters, non-quantitative PCR was performed using the
forward primers: pP1, 5’-
GAAGTCAGATTTGTTCGAAATCTTG-3’; pP2, 5’-
GGAGGTTGTAGAAAGCTCTG-3’ or pC, 5’-
TTCTGCAAACGAGGAATTCAG-3’ to amplify transcripts from
the P1 and P2 promoters, or a region common to both
transcripts, respectively. The common reverse primer was
5’GTAGAGTTTCTTTTGACCTCG- 3’. PCR was carried out at
96°C for 5min, followed by 35 cycles at 96°C for 30s and 56°C
for 1min.
For qPCR, primer-probe sets were purchased from Applied
Biosystems (Warrington, UK): 11β-HSD1 (Hs00194153_m1),
C/EBPβ (Hs00270923_s1), NF-κB/RelA (Hs00153294_m1).
TATA binding protein was used as an internal control (TBP;
Hs00427620_m1).
IL-8 ELISA
IL-8 was measured using the Human IL-8 ELISA
development kit (Peprotech, Rocky Hill, NJ, USA) according to
the manufacturers’ instructions. Briefly, following overnight
incubation with capture antibody and blocking with 1% bovine
serum albumin for 1h, samples and standards (human
recombinant IL-8) were added to the wells, incubated with
detection antibody and then with avidin-HRP conjugate. ABTS
Liquid Substrate (Sigma, Dorset, UK) was used for detection.
Transfections
For siRNA transfections, A549 cells were seeded at a
density of 7.5x104 cells per well of a 12-well plate and
transfected the following day with 80pmol siRNA using
Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions. 24h after transfection, cells were
harvested for protein analysis or further incubated with pro-
inflammatory cytokines for 24h prior to RNA extraction. siRNAs
(Applied Biosystems) comprised scrambled RNA (AM4611
negative control 1), C/EBPβ (ID114495) or NF-κB/RelA (ID
s11914).
For plasmid transfections, A549 cells were transfected as
previously described [11]. Briefly, 1.5×105 cells were seeded
per well of a 6-well plate and transfected the next day using
Lipofectamine 2000 (Invitrogen) with 250ng reporter plasmid
and 250ng pRSV-LacZ (as internal control) or, for transfections
with C/EBPβ mutants, with 50ng of expression plasmid
encoding wild-type chicken C/EBPβ or C/EBPβ in which
Thr220 (equivalent to Thr 235 in human C/EBPβ) has been
mutated to alanine (T220A) or aspartate (T220D) [25,26] (a gift
from E. Kowenz-Leutz and A. Leutz, Max Delbrüeck Centre for
Molecular Medicine, Berlin). Cells were treated the following
day with IL-1α and harvested 24h later. Reporter plasmids
have been described previously [10] and comprise a 5′ deletion
series of the human [27] or rat [10] HSD11B1 P2 promoter,
designated H11β1 or R11β1 (5′-endpoint/3’-endpoint) for
human and rat, respectively; an internal deletion series of
R11β1(−1799/+49), designated RΔ11β1(5′-endpoint of
deletion/3’-endpoint of deletion) and derivatives of
R11β1(−196/+49) with mutations in footprint (FP)3, FP4, or
both FP3 and FP4 [10].
Pro-Inflammatory Cytokine Induction of 11β-HSD1
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Western blot analysis
Cells were harvested directly into lysis buffer (0.125M Tris-
HCL pH 6.8, 2% sodium dodecyl sulphate, 10% glycerol) in the
presence of a protease inhibitor cocktail (P2714; Sigma-
Aldrich, Dorset, UK) and heated at 100°C. Electrophoresis was
carried out on 4-12% NuPage Bis-Tris gels (Invitrogen). After
transfer, blots were probed with antibodies to detect C/EBPβ
(1:500 dilution, Santa Cruz Biotechnology, Santa Cruz, CA),
Thr235 phosphorylated C/EBPβ (1:1000 dilution, Cell
Signaling, Danvers, MA), NF-κB/RelA (1:500 dilution, Santa
Cruz Biotechnology, Santa Cruz, CA) or β-tubulin, used as an
internal control (1:10000 dilution, Chemicon/Millipore, Watford,
UK). Secondary antibodies were anti-rabbit IgG-HRP (1:2000
dilution, Santa Cruz Biotechnology Inc.), anti-mouse IgG-HRP
(1:4000 dilution, Cell Signaling, Danvers, MA) or anti-rabbit IgG
IRDye 800CW (dilution 1:10000; LI-COR Biosciences,
Cambridge, UK). The resulting bands were visualised on
chemiluminescent films (GE Healthcare) using the ECL system
or using the Odyssey Infrared Imaging System (LI-COR
Biosciences), as appropriate.
Immunocytochemistry
Cells were grown on coverslips in 12 well plates, treated with
IL-1α and TNFα, fixed with 4% paraformaldehyde (Sigma-
Aldrich) and then incubated for 16h at 4°C with antibodies
against C/EBPβ or NF-κB/RelA (1:200 dilution, Santa Cruz
Biotechnology) followed by anti-rabbit AlexaFluor 568
secondary antibody (Invitrogen). Cells were then stained with
DAPI (Sigma-Aldrich) for 10min. Coverslips were mounted
using fluoroshield (Sigma) and visualised on an Axiovert 25
fluorescence microscope.
Chromatin immunoprecipitation (ChIP) assays
ChIP assays were carried out using an Upstate EZ ChIP kit
(Millipore, Billerica, MA) as previously described [11] or
following the protocol from Dahl and Collas [28] with
adaptations. Briefly, A549 cells were grown to confluence in
10cm dishes, then treated with IL-1α for 24h. Proteins were
cross-linked to DNA by addition of 1% paraformaldehyde then
cells lysed in 50mM Tris-HCl pH 8.0, 1% sodium dodecyl
sulphate, 10mM EDTA. Chromatin was sheared by sonication
using a Soniprep 150 (MSE; Beckenham, Kent, UK) with 10 x
10s pulses (10 amplitude microns) keeping cells on ice
between pulses. Chromatin aliquots were immunoprecipitated
using Dynabeads-protein A (Invitrogen) with C/EBPβ, NF-κB/
RelA or control IgG antibody (Santa Cruz). DNA was amplified
by qPCR using primers (5'-
AGTCCTGTACAGTCATGAGCTTGG-3' and 5'-
ATTTCCCTGTCAGAGCAGCGATTG-3') to amplify the region
containing the FP3 and FP4 C/EBP binding sites of the
HSD11B1 promoter [10,11] and putative NF-κB binding region
(see Results for details). The primers (5'-
AGGAAGTGTGATGACTCAGGTTT-3' and 5'-
CTCCGGTGGCTTTTTATATCATC-3') were used to amplify the
NF-κB/RelA binding site in the IL-8 promoter. Data are
expressed relative to levels of input DNA in
immunoprecipitations.
Statistical analysis
Data were analyzed by Student’s t test or by one- or two-way
ANOVA followed by post hoc Tukey tests using SigmaStat 2.03
statistical software. Significance was set at p<0.05.
Results
Pro-inflammatory cytokines increase HSD11B1 mRNA
levels in A549 cells via the P2 promoter
Treatment of A549 cells with IL-1α or TNFα robustly
increased levels of mRNA encoding 11β-HSD1 (Figure 1A).
Concomitantly, IL-8 secretion was increased confirming that
A549 cells are cytokine-responsive (data not shown). The gene
encoding 11β-HSD1 is transcribed from one of two promoters,
P1 or P2, which by RNA splicing produce the same protein [9].
Non-quantitative PCR amplification of HSD11B1 mRNA using
primers specific for transcripts originating from promoter P1 or
P2, or a region common to both transcripts (Figure 1B),
showed that pro-inflammatory cytokine induction of HSD11B1
in A549 cells is mediated by the P2 promoter (Figure 1C).
p38 MAPK and C/EBPβ phosphorylation at Thr235 are
implicated in the cytokine-induction of HSD11B1 mRNA
Pro-inflammatory cytokines activate MAPK signalling (p38,
JNK and MEK/ERK). Inhibition of p38 MAPK attenuated the
IL-1α/TNFα induction of HSD11B1 (Figure 2A, B) whereas
inhibition of JNKII had no effect. MEK1/2 inhibition increased
HSD11B1 mRNA above levels seen with IL-1α/TNFα alone
(Figure 3A, B) without affecting CEBPB mRNA levels
(2.27±0.19 vs 2.03±0.09 arbitrary units, for cells without and
with MEK1/2 inhibitor, respectively). None of the inhibitors
affected basal HSD11B1 mRNA levels, in the absence of IL-1α.
IL-1α treatment of A549 cells increased levels of C/EBPβ
mRNA (Figures 2C; 24h time point) and levels of both C/EBPβ-
LAP and C/EBPβ-LIP protein isoforms (time course 2 to 6h),
though levels of C/EBPβ-LAP, the activator isoform
accumulated earlier and to a greater extent than the inhibitory
C/EBPβ-LIP isoform (Figure 2E). CHX incubation of A549 cells
prior to IL-1α/TNFα treatment for 4h attenuated the induction of
HSD11B1 mRNA levels indicating that pro-inflammatory
cytokine induction of HSD11B1 partially depends on de novo
protein synthesis (Figure 2F). Moreover, IL-1α treatment of
A549 cells for 15min resulted in the rapid phosphorylation of C/
EBPβ on Thr235 (Figure 2D). Both the increase in CEBPB
mRNA 24h after addition of IL-1α and the rapid increase in
phosphorylated C/EBPβ-LAP were attenuated by p38 MAPK
inhibition (Figure 2C, D), suggesting that p38 MAPK-mediated
phosphorylation of C/EBPβ is involved in the cytokine induction
of 11β-HSD1 and that this is sustained through increased C/
EBPβ expression. Consistent with this idea, siRNA-mediated
knock-down of C/EBPβ, which did not change basal HSD11B1
mRNA levels, attenuated IL-1α/TNFα-induction of HSD11B1
(Figure 3A-C). In contrast, although IL-1α/TNFα treatment
increased levels of CEBPD mRNA encoding the related C/
EBPδ transcription factor (1.45±0.13 and 1.49±0.17 following
treatment with IL-1α and TNFα, respectively, relative to
untreated cells, 1.00±0.10 arbitrary units; p<0.001), siRNA-
mediated knock-down of C/EBPδ had no effect on the cytokine
Pro-Inflammatory Cytokine Induction of 11β-HSD1
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induction of HSD11B1 (Figure 3). CEBPA mRNA levels were
unaffected by cytokine treatment of A549 cells (0.54±0.21 and
0.79±0.10 following treatment with IL-1α and TNFα,
respectively, relative to untreated cells, 1.00±0.18 arbitrary
units). Overall these results confirm that C/EBPβ is required for
the full cytokine induction of HSD11B1 in A549 epithelial cells.
Figure 1.  Pro-inflammatory cytokines increase levels of
HSD11B1 mRNA from the P2 promoter in A549 cells.  (A)
qPCR measurement of HSD11B1 mRNA following 24h
treatment of A549 cells with IL-1α (10ng/ml) or TNFα (20ng/ml)
(black bars). Controls (white bars) were untreated. All values
are expressed relative to levels in untreated cells, arbitrarily set
to 1 and are mean ± SEM; n≥6. *, significantly different from
control. ***, p<0.0001. (B) Schematic representation of the
HSD11B1 gene showing exons 1A, 1B, 2 and 3 (open boxes)
and the corresponding start of transcription for the P1 and P2
promoters (bent arrows). The forward primers used to amplify
transcripts from P1 (pP1), P2 (pP2) or a region common to
transcripts originating from both P1 and P2 promoters (pC) are
indicated. The reverse primer was used for all PCR reactions.
(C) Gel showing PCR products from transcripts initiating at P1
(1, 267bp), P2 (2, 285bp) and a region common to transcripts
originating from either promoter (C; 152bp) produced using
cDNA from untreated (Con) A549 cells or following 24h
treatment with IL-1α or TNFα. CCRF-CEM human leukaemia
cells, which express HSD11B1 predominantly from the P1
promoter, served as a positive control for P1-initiated
transcripts. All PCR products were run together and in the
same gel.
doi: 10.1371/journal.pone.0075874.g001
siRNA-mediated knock-down of NF-κB/RelA attenuates
HSD11B1 induction by IL-1α/TNFα
NF-κB/RelA is required for the pro-inflammatory cytokine
induction of mRNA encoding 11β-HSD1 in murine
mesenchymal cells [13]. However, a role in epithelial cells has
not been demonstrated. In human A549 cells, RELA mRNA
levels were increased following treatment with IL-1α or TNFα
(data not shown). siRNA was used to test whether NF-κB/RelA
also plays a role in pro-inflammatory cytokine induction of
HSD11B1 in human A549 epithelial cells. Knock-down of NF-
κB/RelA (Figure 3A) did not change basal HSD11B1 mRNA
levels but attenuated the induction of HSD11B1 mRNA by
IL-1α/TNFα (Figure 3B, C), demonstrating a role for the NF-κB/
RelA pathway in the cytokine induction of HSD11B1.
C/EBPβ and NF-κB/RelA locate to the nucleus in
cytokine-treated A549 cells
Immunofluorescent staining of A549 cells showed nuclear
localisation of C/EBPβ irrespective of cytokine treatment
(Figure 4A-C, J-L). In agreement with the literature, NF-κB/
RelA was restricted to the cytoplasm in untreated A549 cells
(Figure 4D, G, M) but rapidly translocated to the nucleus
following addition of IL-1α or TNFα (Figure 4E, H, N), largely
returning to the cytoplasm 24h after treatment (Figure 4F, I, O).
Pro-inflammatory cytokine induction of the P2
promoter of HSD11B1 requires the C/EBPβ binding
sites, FP3 and FP4
To localise the region of the HSD11B1 P2 promoter
responsible for pro-inflammatory cytokine induction of 11β-
HSD1, A549 cells were transfected with luciferase reporter
constructs encoding regions of the human or rat HSD11B1
gene. IL-1α treatment induced promoter-reporter constructs
encoding -2700 to +78 of the human HSD11B1 P2 promoter
(the start of transcription is designated +1) or -1799 to +49 of
the rat Hsd11b1 promoter (Figure 5A). Promoter activity was
unaffected by 5’-deletion of the human HSD11B1 promoter to
-440 or of the rat Hsd11b1 promoter to -146, positioning the
cytokine responsive region in the proximal region of the
promoter. Furthermore, deletion of the region between -311
and -125 of the rat promoter abolished cytokine induction
(Figure 5B), localising an essential region between -196 and
-125 (though this could extend further 3’). This region, highly
conserved between the rat and human HSD11B1 genes,
encompasses the C/EBP binding sites FP3 and FP4, which are
critical for HSD11B1 regulation by a variety of stimuli in a
variety of cell types [10,11,24,29–31]. Mutation of FP3 or FP4
alone or in combination abolished induction of the promoter by
IL-1α (Figure 5C), showing that both sites are necessary for
cytokine induction of 11β-HSD1 and implicating C/EBPβ as a
key mediator of the response.
IL-1α increases binding of C/EBPβ, but not NF-κB/RelA,
to the region encompassing FP3 and 4 in the P2
promoter of HSD11B1
The above experiments show that FP3 and FP4, known C/
EBPβ binding sites in the HSD11B1 promoter (Figure 6A), are
Pro-Inflammatory Cytokine Induction of 11β-HSD1
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Figure 2.  Inhibition of p38 MAPK attenuates IL-1α induction of mRNAs encoding 11β-HSD1 and C/EBPβ and prevents IL-1α
induced C/EBPβ phosphorylation.  (A, B) qPCR measurement of levels of mRNA encoding 11β-HSD1 in A549 cells without
inhibitor (-) or pre-incubated for 1h with inhibitors of p38 MAPK (p38, SB203580; 10µM), JNK II (SP600125; 20µM) or MEK I
(PD0325901; 0.5µM) prior to 24h treatment with IL-1α (A) or TNFα (B) (black bars). White bars; no cytokine treatment. All data are
expressed relative to levels in untreated cells (no inhibitor, no cytokine), arbitrarily set to 1, and are mean ± SEM; n≥3. *,
significantly different from IL-1α-stimulated control. *, p<0.05; **p<0.001. (C) qPCR measurements of levels of mRNA encoding C/
EBPβ in cells treated for 24h with IL-1α with (p38 inhibitor), or without (-) prior addition of p38 MAPK inhibitor. Data are expressed
relative to levels in untreated control cells (no inhibitor, no cytokine), arbitrarily set to 1, and are mean ± SEM; n≥6. *, significantly
different from IL-1α-stimulated control. *, p<0.05. #, significantly different from unstimulated cells. ##, p<0.001. (D) Western blot
showing levels of phosphorylated C/EBPβ-LAP (P-C/EBPβ-LAP); upper image) in untreated A549 cells (-p38 MAPK, -IL-1α; white
bar), or following 15min treatment with IL-1α alone (-p38 MAPK, +IL-1α; black bar) or with prior addition of p38 MAPK inhibitor for 1h
(+p38 MAPK, +IL-1α; grey bar; SB203580, 50µM). The blot (20µg protein/lane) was stripped and reprobed with C/EBPβ antibody
(bottom membrane) to detect total C/EBPβ-LAP. Protein bands were quantified using the Odyssey Infrared Imaging System and the
ratio of P-C/EBPβ-LAP/total C/EBPβ-LAP calculated. Data are expressed relative to levels in untreated cells (no inhibitor, no
cytokine), arbitrarily set to 1, and are mean ± SEM; n=3. *, p<0.05; **, p<0.001. (E) Western blot showing increased levels of C/
EBPβ-LAP and C/EBPβ-LIP isoforms after IL-1α treatment for up to 6h, compared to control untreated cells (C). (F) qPCR
measurement of levels of mRNA encoding 11β-HSD1 in A549 cells incubated for 1h with CHX (+) or without CHX (-) followed by
IL-1α/TNFα treatment for 4h or control (Con). Data are expressed relative to levels in untreated cells (no CHX, no cytokine),
arbitrarily set to 1, and are mean ± SEM; n=3. *, p<0.05 significant effect of CHX. #, significantly different to untreated cells (no
CHX, no cytokine). #, p<0.05; # #, p<0.001.
doi: 10.1371/journal.pone.0075874.g002
Pro-Inflammatory Cytokine Induction of 11β-HSD1
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required for pro-inflammatory cytokine induction of HSD11B1.
As predicted, C/EBPβ binding to the FP3/FP4 region of the
HSD11B1 promoter was increased in IL-1α (Figure 6A, B) and
in TNFα-treated cells (data not shown). In contrast, although
IL-1α caused NF-κB/RelA to bind to the promoter of the gene
encoding IL-8 in A549 cells (data not shown), no binding to the
HSD11B1 promoter was observed (Figure 6B), despite the
prediction of putative binding sites for NF-κB in this region
(Figure 6A).
C/EBPβ phosphorylation at Thr235 is implicated in
cytokine-induction of HSD11B1 transcription
To test the role of C/EBPβ phosphorylation in the cytokine
regulation of HSD11B1, A549 cells were transfected with
expression plasmids encoding the chicken homologue of C/
EBPβ or mutants in which Thr220 (equivalent to Thr235 in
human C/EBPβ) was changed to alanine (C/EBPβ-T220A,
abolishing phosphorylation at this key residue) or to aspartate
(C/EBPβ-T220D, mimicking constitutive phosphorylation)
[25,26]. Compared to the wild-type (WT) C/EBPβ, transfection
Figure 3.  siRNA mediated knock-down of C/EBPβ or NF-
κB/RelA attenuates the pro-inflammatory cytokine
induction of HSD11B1.  (A) Representative western blots
(12.5µg protein/lane) showing levels of C/EBPβ (left panel), C/
EBPδ (middle panel) and NF-κB/RelA (right panel) 24h after
transfection of cells with scrambled RNA (Scr; as control) or
siRNAs targeting C/EBPβ, C/EBPδ or NF-κB/RelA. Blots were
stripped and reprobed with β-tubulin antibody, as loading
control. In the C/EBPδ and NF-κB/RelA westerns, all samples
were analysed in the same gel but not all in adjacent lanes. (B,
C) Real-time PCR measurement of HSD11B1 mRNA in
untreated cells (white bars) or cells treated for 24h with IL-1α
(B; black bars) or TNFα (C; black bars), 24h after transfection
with scrambled RNA (Scr) or siRNA targeting C/EBPβ (β), C/
EBPδ (δ) or NF-κB/RelA (RelA). Data are expressed relative to
levels in untreated cells transfected with scrambled RNA,
arbitrarily set to 1. Values, in arbitrary units (AU), are mean ±
SEM; n≥5. **, p<0.001, compared to cells transfected with
scrambled RNA followed by IL-1α/TNFα treatment.
doi: 10.1371/journal.pone.0075874.g003
with C/EBPβ-T220A attenuated cytokine induction of HSD11B1
whereas C/EBPβ-T220D had no effect on HSD11B1 induction,
but increased basal HSD11B1 mRNA levels in vehicle treated
cells (Figure 6C).
Discussion
We have previously shown that the P2 promoter is active in
A549 epithelial cells, with little or no P1 activity [9], consistent
with data from others showing the P2 promoter predominates
in untreated A549 cells [32]. As in mesenchymal cells [13], pro-
inflammatory cytokines increase activity of the C/EBP-
dependent P2 promoter of HSD11B1 [9] in A549 cells and this
is associated with increased binding of C/EBPβ to the FP3/FP4
region of the promoter, similar to TNFα induction of HSD11B1
in human HepG2 hepatoma cells [12]. Here, we also found NF-
κB/RelA is required for IL-1α induction of the P2 promoter of
HSD11B1 in A549 epithelial cells, as it is in murine
Figure 4.  C/EBPβ and NF-κB/RelA are located in the
nucleus in IL-1α/TNFα treated A549 cells.  C/EBPβ is
located in the nucleus in untreated and cytokine-treated A549
cells whereas NF-κB/RelA rapidly translocates to the nucleus in
response to cytokine treatment. Micrographs show A549 cells
15min or 24h after addition of IL-1α (upper panels) or TNFα
(lower panels), compared to untreated (control) cells. Red
fluorescence shows immunodetection of C/EBPβ (A-C and J-L)
or NF-κB/RelA (D-I and M-O). DAPI (blue) was used to stain
nuclei. All micrographs were obtained with an objective
magnification of x40.
doi: 10.1371/journal.pone.0075874.g004
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Figure 5.  The proximal region is required for pro-
inflammatory cytokine induction of the P2 promoter of
HSD11B1.  (A) Transiently transfected A549 cells showing
IL-1α-induction of luciferase reporter constructs encoding the
human HSD11B1 P2 promoter; H11β1(-2700/+78) and
H11β1(-440/+78), and the rat Hsd11b1 P2 promoter;
R11β1(-1799/+49) and R11β1(-196/+49). (B) Internal deletions
of the rat Hsd11b1 P2 promoter (-1799/+49) that removed
-1290 to -125 R∆11β1(-1290/-125) or -311 to -125
R∆11β1(-311/-125) abolished IL-1α induction of promoter
activity. (C) Mutation of FP3 and/or FP4 within the proximal
promoter (-196/+49) of the rat Hsd11b1 promoter abolished
induction by IL-1α. Black bars, IL-1α-treated cells; white bars,
untreated. Promoter activity is expressed as luciferase/β-
galactosidase (internal control) activity. Values are fold
induction relative to untreated cells transfected with the same
plasmid (means ± SEM; n≥6). Absolute luciferase/β-
galactosidase values (without normalization) are shown in the
bars of the graph. *, significantly different from untreated cells
transfected with the same plasmid. **, p<0.001; ***, p<0.0001.
doi: 10.1371/journal.pone.0075874.g005
Figure 6.  Chromatin immunoprecipitation assays show
binding of C/EBPβ, but not of NF-κB/RelA, to the HSD11B1
P2 promoter following IL-1α treatment.  (A) Sequence of the
region of the P2 promoter of the HSD11B1 gene that is
essential for induction by IL-1α, which includes the previously
described C/EBP binding sites, FP3 and FP4 [10] (boxed). The
transcription start site (+1) is indicated by a bent arrow.
Putative NF-κB binding sites (predicted using AliBaba 2.1
software; Biobase, Biological databases) are underlined.
Primers used in ChIP assays are indicated by arrows under the
sequence. (B) qPCR quantification of ChIP assays showed C/
EBPβ but not NF-κB binding to the P2 promoter of HSD11B1 in
cells treated with IL-1α (black bars). White bars, untreated
cells. Values, in arbitrary units (AU), are mean ± SEM; n=5. *,
p<0.05. (C) qPCR measurements of levels of mRNA encoding
11β-HSD1 in untreated (white bars) or following IL-1α
treatment (black bars) of A549 cells transiently transfected with
plasmids (50ng) encoding wild-type (WT) chicken C/EBPβ or
mutants C/EBPβ(T220A) or C/EBPβ(T220D), abolishing or
mimicking, respectively, constitutive phosphorylation of T220
(equivalent to T235 in human C/EBPβ). Data, in arbitrary units
(AU), are expressed relative to levels in IL-1α-treated cells
transfected with WT C/EBPβ, arbitrarily set to 100 and are
mean ± SEM; n=6. **, p<0.001 compared to untreated cells
transfected with WT C/EBPβ; #, p<0.05 compared to cells
transfected with C/EBPβ(T220A) and treated with IL-1α.
doi: 10.1371/journal.pone.0075874.g006
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mesenchymal cells [13], though a direct interaction of NF-κB/
RelA with the HSD11B1 promoter in the latter was not tested.
Our data show that the requirement for NF-κB/RelA for pro-
inflammatory cytokine induction of HSD11B1 in human
epithelial cells does not involve direct binding to the P2
promoter.
Previous data have implicated p38 MAPK in the pro-
inflammatory cytokine induction of 11β-HSD1 [12,13,33]. p38
MAPK regulates mRNA stability and the activity of C/EBPβ by
phosphorylation [34,35]. Here, IL-1α/TNFα treatment increased
Thr235 phosphorylation of C/EBPβ and this was attenuated by
p38 MAPK inhibition, as was the pro-inflammatory cytokine up-
regulation of C/EBPβ mRNA levels. This occurred concurrently
with decreased HSD11B1 mRNA levels, suggesting that a p38
MAPK-C/EBPβ pathway mediates this process. MEK inhibition
increased HSD11B1 mRNA levels, though whether this was via
MEK or ERK (ERK is activated by MEK phosphorylation) was
not investigated. The relevance of this remains unknown but
may reflect stabilisation of the short-lived C/EBPβ or another
factor required for HSD11B1 transcription.
As for myriad other stimuli, pro-inflammatory cytokine
induction of HSD11B1 requires C/EBPβ to bind to the FP3/4
region of the P2 promoter, and phosphorylation of C/EBPβ at
Thr235 is implicated in the cytokine-induced up-regulation of
HSD11B1. Ectopic expression of C/EBPβ mutants in
transfected A549 cells provides direct evidence that Thr235
phosphorylation is critical for the IL-1α induction of HSD11B1.
Indeed, abolition of phosphorylation at the equivalent threonine
of chicken C/EBPβ by mutation to alanine (T220A), attenuated
cytokine induction of the HSD11B1 promoter, whilst ectopic
expression of constitutively active C/EBPβ (mutation of Thr220
to aspartate) increased basal activity of the HSD11B1 promoter
but did not affect the level of cytokine-induced HSD11B1
mRNA, which remained similar to that conferred by wild type C/
EBPβ. However, other post-translational modifications of C/
EBPβ are also likely to play a role in pro-inflammatory cytokine
induction of HSD11B1 as mutation of threonine 220 to alanine
did not totally abolish the effect of IL-1α, though we cannot rule
out an effect of endogenous non-mutated C/EBPβ.
Thus, p38 MAPK, C/EBPβ and NF-κB/RelA are required for
the full induction of HSD11B1 in human A549 epithelial cells by
pro-inflammatory cytokines and their relative importance may
differ according to cell type and activating stimulus.
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